

**Authors:** Edward Schwarz, Jamie Esteban, Hamidreza Yazdi, John-Jairo Aguilera-Correa

**QUESTION 3:** Is the biofilm on orthopaedic implant surfaces permeable to neutrophils and macrophages *in vivo*? Are these innate immune cells (meaning any macrophages or neutrophils) capable of engulfing and killing bacteria?

**RESPONSE:** A mature bacterial biofilm has limited permeability to neutrophils and macrophages. Those that get through are clinically ineffective at eradicating biofilm bacteria. While neutrophils and macrophages are capable of engulfing and killing planktonic bacteria, they are not innately capable of effectively engulfing and killing sessile bacteria in biofilm.

**LEVEL OF EVIDENCE:** Strong

**DELEGATE VOTE:** Agree: 100%, Disagree: 0%, Abstain: 0% (Unanimous, Strongest Consensus)

### PRE-MEETING RATIONALE

The most important pathogenic mechanism involved in implant-related infections is the ability of the microorganisms to form a biofilm [1], which leads to protection against environmental stress, host immune defense and antimicrobials [2]. The first cells arriving at the infection site are the neutrophils and macrophages [3]. The permeability and the phagocytosis ability of these immune cells have mainly been evaluated in two types of infection: cystic fibrosis [4–8] and device related infection, mainly catheter-related infection [9–17] and periprosthetic infection [18].

Neutrophils are innate immune cells capable of secreting an arsenal of toxic oxygen species, degrading enzymes, defensins and lipid inflammatory mediators to fight off infection [6]. These cells have shown the ability of sticking but not penetrating into a mature biofilm and phagocytizing biofilm encased microorganisms [4–8,10,11,14,19–23]. The exopolymeric substances of the biofilm matrix seem to be involved in the formation of neutrophil extracellular traps in biofilm of *Streptococcus suis* [21], *Candida albicans* [10] and *Candida glabrata* [11]. Data shows that neutrophils can destroy a two to six day old *Staphylococcus aureus* (*S. aureus*) biofilm, but a mature biofilm is capable of resisting penetration by these cells [24].

Guenther et al. studied the different behavior of polymorphonuclear neutrophils (PMNs) towards the biofilm formed by either *S. aureus* or *Staphylococcus epidermidis* (*S. epidermidis*). In the case of biofilm formed by *S. aureus*, the PMNs were observed to move across and scavenge bacteria along their path. Conversely, PMNs in contact with *S. epidermidis* biofilm were nearly immobile and phagocytized only bacteria in close proximity. Why biofilms of *S. aureus* appear more sensitive to a PMN attack compared to those produced by *S. epidermidis* is not well understood [19]. Insights on the behavior of biofilm formed by *S. epidermidis* have been offered by the *in vitro* and *in vivo* studies of Kristian et al. These authors found that *S. epidermidis* biofilms triggered higher levels of complement activation in terms of C3a formation than planktonic wild-type bacteria and isogenic *ica*-negative bacteria. On the other hand, a decreased deposition of immunoglobulin G (IgG) and C3b was observed in biofilm-embedded bacteria. This could possibly explain the evasion of PMNs killing [25].

Alhede et al. evaluated the role of immune system against biofilm formed by *Pseudomonas aeruginosa*. They demonstrated that both *in vitro* and *in vivo* biofilms of *Pseudomonas aeruginosa* produce


ICM Philly










a shield of excreted rhamnolipids, which offers protection from the bactericidal activity of PMNs [26].

Arciola et al. did an extensive study of biofilm formed by *Staphylococcus* on an implant surface. Based on their work, PMNs were found to surround biofilm and become activated, but PMNs were not able to migrate into the biofilm, probably because of a lack of a chemotactic signal as well as by hindrance of migration into the “slimy” material. Thus, the inability of PMNs to penetrate biofilm results in progression of implant related infections. The activation of PMNs and their attempt to kill bacteria results in secretion of numerous cytotoxic and proteolytic enzymes that cannot act against bacteria but results in damaging and destroying the surrounding host tissues [27].

Macrophages become the prevailing cells and remain at the infection site a high concentration for several weeks and they are related to recognition, phagocytosis, secretion of enzymes, cytokines, chemokines and growth factors, to destroy and digest the phagocytized pathogens [3]. These cells can penetrate into a mature biofilm in a similar way as neutrophils, and phagocytize biofilm encased microorganisms, but not destroying them [9,12,13,18]. Moreover, these sessile phagocytized bacteria can even persist into peri-implant tissue inside macrophagic cells not only in experimental models, but also in the tissues of patients with intravenous catheters colonized by different bacteria [16,17]. *S. aureus* prosthetic infection in vivo model showed that limited bacterial macrophage uptake is due to inflammatory attenuation by *S. aureus* biofilm [13], which favor the transformation from M1 macrophages presents a high antimicrobial activity to M2 type inherently possesses less antimicrobial activity [13], and the cell death induction though leukocidin A/B [28] and human leukocyte antigen production [18]. At the site of staphylococcus biofilm infection, macrophages exhibit: down-regulation of interleukin (IL)-1 $\beta$ , tumor necrosis factor, CXCL2 and CCL2 expression, reduced bacterial uptake, minimal iNOS expression and consequent low efficiency in killing phagocytized bacteria and reduced induction of lymphocyte production of interferon- $\gamma$ . These scavenging cells appear able to migrate into the biofilm but cannot clear the site from the pathogen causing the infection as their bactericidal activity appears compromised [27].

## REFERENCES

- [1] Tande AJ, Patel R. Prosthetic joint infection. *Clin Microbiol Rev.* 2014;27:302–345. doi:10.1128/CMR.00111-13.
- [2] Costerton JW, Lewandowski Z, Caldwell DE, Korber DR, Lappin-Scott HM. Microbial biofilms. *Annu Rev Microbiol.* 1995;49:711–745. doi:10.1146/annurev.mi.49.100195.003431.
- [3] da Silva Domingues JF, van der Mei HC, Busscher HJ, van Kooten TG. Phagocytosis of bacteria adhering to a biomaterial surface in a surface thermodynamic perspective. *PLoS ONE.* 2013;8:e70046. doi:10.1371/journal.pone.0070046.
- [4] Häscher GM, Brenner-Weiss G, Prior B, Wagner C, Obst U. The extracellular polymer substance of *Pseudomonas aeruginosa*: too slippery for neutrophils to migrate on? *Int J Artif Organs.* 2008;31:796–803.
- [5] Häscher GM, Prior B, Brenner-Weiss G, Obst U, Overhage J. The *Pseudomonas* quinolone signal (PQS) stimulates chemotaxis of polymorphonuclear neutrophils. *J Appl Biomater Funct Mater.* 2014;12:21–26. doi:10.5301/jabfm.5000204.
- [6] Jesaitis AJ, Franklin MJ, Berglund D, Sasaki M, Lord CI, Bleazard JB, et al. Compromised host defense on *Pseudomonas aeruginosa* biofilms: characterization of neutrophil and biofilm interactions. *J Immunol.* 2003;171:4329–4339.
- [7] Parks QM, Young RL, Poch KR, Malcolm KC, Vasil ML, Nick JA. Neutrophil enhancement of *Pseudomonas aeruginosa* biofilm development: human F-actin and DNA as targets for therapy. *J Med Microbiol.* 2009;58:492–502. doi:10.1099/jmm.0.005728-0.
- [8] Takeoka K, Ichimiya T, Yamasaki T, Nasu M. The in vitro effect of macrolides on the interaction of human polymorphonuclear leukocytes with *Pseudomonas aeruginosa* in biofilm. *Chemotherapy* 1998;44:190–197. doi:10.1159/000007114.
- [9] Hanke ML, Heim CE, Angle A, Sanderson SD, Kielian T. Targeting macrophage activation for the prevention and treatment of *Staphylococcus aureus* biofilm infections. *J Immunol.* 2013;190:2159–2168. doi:10.4049/jimmunol.1202348.
- [10] Johnson CJ, Cabezas-Olcoz J, Kernien JF, Wang SX, Beebe DJ, Huttenlocher A, et al. The extracellular matrix of *Candida albicans* biofilms impairs formation of neutrophil extracellular traps. *PLoS Pathog.* 2016;12:e1005884. doi:10.1371/journal.ppat.1005884.
- [11] Johnson CJ, Kernien JF, Hoyer AR, Nett JE. Mechanisms involved in the triggering of neutrophil extracellular traps (NETs) by *Candida glabrata* during planktonic and biofilm growth. *Sci Rep.* 2017;7:13065. doi:10.1038/s41598-017-13588-6.
- [12] Spiliopoulou AI, Krevvata MI, Kolonitsiou F, Harris LG, Wilkinson TS, Davies AP, et al. An extracellular *Staphylococcus epidermidis* polysaccharide: relation to polysaccharide intercellular adhesion and its implication in phagocytosis. *BMC Microbiol.* 2012;12:76. doi:10.1186/1471-2180-12-76.
- [13] Thurlow LR, Hanke ML, Fritz T, Angle A, Aldrich A, Williams SH, et al. *Staphylococcus aureus* biofilms prevent macrophage phagocytosis and attenuate inflammation in vivo. *J Immunol.* 2011;186:6585–6596. doi:10.4049/jimmunol.1002794.
- [14] Boelens JJ, Dankert J, Murk JL, Weening JJ, van der Poll T, Dingemans KP, et al. Biomaterial-associated persistence of *Staphylococcus epidermidis* in pericatheter macrophages. *J Infect Dis.* 2000;181:1337–1349. doi:10.1086/315369.
- [15] Broekhuizen CAN, de Boer L, Schipper K, Jones CD, Quadri S, Feldman RG, et al. Peri-implant tissue is an important niche for *Staphylococcus epidermidis* in experimental biomaterial-associated infection in mice. *Infect Immun.* 2007;75:1129–1136. doi:10.1128/IAI.01262-06.
- [16] Broekhuizen CAN, Schultz MJ, van der Wal AC, Boszhard L, de Boer L, Vandembroucke-Grauls CMJE, et al. Tissue around catheters is a niche for bacteria associated with medical device infection. *Crit Care Med.* 2008;36:2395–2402. doi:10.1097/CCM.0b013e3181818268.
- [17] Broekhuizen C a. N, Sta M, Vandembroucke-Grauls CMJE, Zaat S a. J. Microscopic detection of viable *Staphylococcus epidermidis* in peri-implant tissue in experimental biomaterial-associated infection, identified by bromodeoxyuridine incorporation. *Infect Immun.* 2010;78:954–962. doi:10.1128/IAI.00849-09.
- [18] Scherr TD, Hanke ML, Huang O, James DBA, Horswill AR, Bayles KW, et al. *Staphylococcus aureus* biofilms induce macrophage dysfunction through leukocidin AB and alpha-toxin. *MBio.* 2015;6. doi:10.1128/mBio.01021-15.
- [19] Guenther F, Stroh P, Wagner C, Obst U, Häscher GM. Phagocytosis of staphylococci biofilms by polymorphonuclear neutrophils: *S. aureus* and *S. epidermidis* differ with regard to their susceptibility towards the host defense. *Int J Artif Organs.* 2009;32:565–573.
- [20] Leid JG, Shirliff ME, Costerton JW, Stoodley P. Human leukocytes adhere to, penetrate, and respond to *Staphylococcus aureus* biofilms. *Infect Immun.* 2002;70:6339–6345.
- [21] Ma F, Yi L, Yu N, Wang G, Ma Z, Lin H, et al. *Streptococcus suis* serotype 2 biofilms inhibit the formation of neutrophil extracellular traps. *Front Cell Infect Microbiol.* 2017;7:86. doi:10.3389/fcimb.2017.00086.
- [22] Maurer S, Fouchard P, Meyle E, Prior B, Häscher GM, Dapunt U. Activation of neutrophils by the extracellular polymeric substance of *S. epidermidis* biofilms is mediated by the bacterial heat shock protein GroEL. *J Biotechnol Biomater.* 2015;5:176–183.
- [23] Zimmerli W, Lew PD, Cohen HJ, Waldvogel FA. Comparative superoxide-generating system of granulocytes from blood and peritoneal exudates. *Infect Immun.* 1984;46:625–630.
- [24] Hirschfeld J. Dynamic interactions of neutrophils and biofilms. *J Oral Microbiol.* 2014;6:26102.
- [25] Kristian SA, Birkenstock TA, Sauder U, Mack D, Götz F, Landmann R. Biofilm formation induces C3a release and protects *Staphylococcus epidermidis* from IgG and complement deposition and from neutrophil-dependent killing. *J Infect Dis.* 2008;197:1028–1035. doi:10.1086/528992.
- [26] Alhede M, Bjarnsholt T, Givskov M, Alhede M. *Pseudomonas aeruginosa* biofilms: mechanisms of immune evasion. *Adv Appl Microbiol.* 2014;86:1–40. doi:10.1016/B978-0-12-800262-9.00001-9.
- [27] Arciola CR, Campoccia D, Speziale P, Montanaro L, Costerton JW. Biofilm formation in *Staphylococcus* implant infections. A review of molecular mechanisms and implications for biofilm-resistant materials. *Biomaterials.* 2012;33:5967–5982. doi:10.1016/j.biomaterials.2012.05.031.
- [28] Melehan JH, James DBA, DuMont AL, Torres VJ, Duncan JA. *Staphylococcus aureus* Leukocidin A/B (LukAB) Kills Human Monocytes via Host NLRP3 and ASC when extracellular, but not intracellular. *PLoS Pathog.* 2015;11:e1004970. doi:10.1371/journal.ppat.1004970.

